← TrialMatch
HomeTrials

BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndro

The aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients registered in SWEDEHEART will be included.

Condition(s)Takotsubo Syndrome
StatusRecruiting
PhasePhase 4
Study typeInterventional
SummaryThe aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients registered in SWEDEHEART will be included.
Who can participateInclusion Criteria: 1. Age ≥ 18 years. 2. A clinical diagnosis of TS (see definition 2.1), including an ejection fraction (EF) ˂ 50 % at baseline 3. Written informed consent obtained Exclusion Criteria: 1. Previous randomization in the trial 2. Any concomitant condition resulting in a life expectancy of less than one month 3. Previously diagnosed left ventricular ejection fraction \<50% 4. Known cardiomyopathy (except previous Takotsubo syndrome) 5. Known hemodynamically significant valve disease (moderate or severe aortic/mitral regurgitation) or stenosis 6. Heart transplant or left ventricular assist device recipient 7. Most recent (within the most recent 3 months) haemoglobin ˂10 g/dL 8. Systolic blood pressure \<80 mm Hg at screening 9. Estimated glomerular filtration rate \<30 mL/min/
Ages18 Years
SexAll
Lead sponsorVastra Gotaland Region
LocationsAarhus, Denmark; Copenhagen, Denmark; Oslo, Norway; Östersund, Jämtland Härjedalen, Sweden; Jönköping, Region Jönköping, Sweden; Trollhättan, Västra Götalands Region, Sweden (+10 more sites)
Start date2020-12-14
NCT IDNCT04666454
Official listinghttps://clinicaltrials.gov/study/NCT04666454

🔍 Search all trials →